Genmab A/S Files 6-K, Incorporates Articles of Association
Ticker: GNMSF · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, corporate-governance
TL;DR
Genmab filed a 6-K on 9/30/25, updating its Articles of Association for investors.
AI Summary
Genmab A/S filed a Form 6-K on September 30, 2025, for the month of September 2025. This report is incorporated by reference into several of Genmab's S-8 registration statements, including File No. 333-284876. The filing includes Genmab's Articles of Association as Exhibit 3.1.
Why It Matters
This filing ensures that Genmab's governing documents are publicly available and incorporated into its SEC filings, providing transparency for investors regarding the company's structure and regulations.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates existing company documents and does not introduce new financial or operational risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (registration_statement) — Incorporated by reference
- 333-253519 (registration_statement) — Incorporated by reference
- 333-262970 (registration_statement) — Incorporated by reference
- 333-277273 (registration_statement) — Incorporated by reference
- 333-284876 (registration_statement) — Incorporated by reference
- Exhibit 3.1 (document) — Articles of Association
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K filing is to report information for the month of September 2025 and to incorporate Genmab's Articles of Association as Exhibit 3.1 into its existing registration statements.
Which SEC registration statements does this 6-K filing get incorporated into?
This 6-K filing is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
What is included as an exhibit in this filing?
Exhibit 3.1, the Articles of Association of Genmab A/S, is included in this filing.
What is the filing date and period of report for this 6-K?
The filing date and the period of report for this 6-K filing are both September 30, 2025.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 211 words · 1 min read · ~1 pages · Grade level 14.2 · Accepted 2025-09-30 11:27:34
Filing Documents
- gmab_20250930xxaoa6k.htm (6-K) — 13KB
- gmab_20250930xxex3d1.htm (EX-3.1) — 226KB
- 0001434265-25-000085.txt ( ) — 240KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 3.1 Articles of Association SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE SEPTEMBER 30, 2025